[
  {
    "clause_index": 6,
    "start_char": 2600,
    "end_char": 2648,
    "original": "1.4. Available Margin  is defined on Exhibit A .",
    "modified": "1.4. The Minimum Required Margin, as outlined in Exhibit A, shall apply.\n\nIn this version, the term \"Available Margin\" has been replaced with \"Minimum Required Margin,\" implying a shift from an option to a requirement, thereby strengthening the obligation.",
    "contradiction_score": 0.9378426671028137,
    "kept": true
  },
  {
    "clause_index": 7,
    "start_char": 2648,
    "end_char": 2824,
    "original": "1.5. Business Plan shall mean the business plan attached as Exhibit B  hereto, which business plan may be amended from time to time by mutual agreement of Qualigen and Sekisui.",
    "ollama_generated": "1.5. The term \"Business Plan\" refers to the business plan appended as Exhibit B in this agreement, which may undergo revisions or updates at any point, as long as both Qualigen and Sekisui mutually agree that such amendments have been appropriately made and are duly binding. In the event of disagreement on whether an amendment constitutes a valid update to the Business Plan, either party may request mediation to reach a resolution.",
    "contradiction_score": 0.001217834185808897,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 9,
    "start_char": 2862,
    "end_char": 3068,
    "original": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020 1.7. Competent Authority  shall mean the governmental authority in a member state of the European Union which has competence in relation to the Products.",
    "ollama_generated": "Alteration: Shift responsibility from Ritter Pharmaceuticals Inc. to the recipient of the agreement.\n\nClause:\nRecipient shall bear the responsibility of identifying the Competent Authority, which refers to the governmental body in a member state of the European Union that holds jurisdiction over the Products, as defined by the governing laws and regulations of said union.",
    "contradiction_score": 0.3356170654296875,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 11,
    "start_char": 3256,
    "end_char": 3300,
    "original": "1.9. Effective Date  shall mean May 1, 2016.",
    "ollama_generated": "1.9. The Effective Date shall be deemed to be May 1, 2016, subject to the parties' mutual agreement on an alternative date, in which case the Effective Date shall be the agreed-upon date.",
    "contradiction_score": 0.04277660325169563,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 20,
    "start_char": 5115,
    "end_char": 5337,
    "original": "1.18. Products shall mean all of Qualigen\u2019s current and future products, including without limitation those listed on Exhibit D, for sale under the trade names listed with such products, including any improvements thereto.",
    "ollama_generated": "1.18. For the purposes of this Agreement, \"Products\" shall encompass all existing and subsequent items developed by Qualigen, regardless of whether they are specifically mentioned in Exhibit D or not, as well as those sold under the designated trade names associated with them. It is understood that any modifications or advancements made to these Products shall also be considered part of the definition of \"Products.\"",
    "contradiction_score": 0.004895361606031656,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 28,
    "start_char": 7868,
    "end_char": 7977,
    "original": "1.26. Third Party  shall mean a party other than Sekisui or Qualigen or any Affiliate of Sekisui or Qualigen.",
    "ollama_generated": "1.26. For the purposes of this Agreement, the term \"Third Party\" refers to any entity not directly associated with Sekisui, Qualigen, or any affiliated organizations of either party. In such cases, it is understood that these Third Parties bear their own responsibilities and liabilities in relation to the agreement, unless expressly stated otherwise.",
    "contradiction_score": 0.00158893212210387,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 32,
    "start_char": 10342,
    "end_char": 10836,
    "original": "2.4. Qualigen Retained Customers.  In addition to the retention of the Qualigen Instruments, Qualigen shall be permitted to continue selling the existing Qualigen products directly to the Qualigen Retained Customers. However, Qualigen shall not engage any distributors (whether exclusive or non-exclusive) other than Sekisui for the Qualigen Retained Customers. Sekisui shall not, and shall cause its subdistributors not to, market, rent or sell any Products to the Qualigen Retained Customers.",
    "ollama_generated": "2.4. Permitted Sales to Qualigen Retained Customers. Sekisui grants Qualigen the right to continue selling existing Qualigen products directly to the Qualigen Retained Customers. Nevertheless, Qualigen is not restricted from partnering with distributors other than Sekisui for all other customer bases. Sekisui and its subdistributors shall be allowed to market, rent, or sell Products to any customers excluding the Qualigen Retained Customers.\n\nIn this revised clause, the responsibility of not engaging distributors other than Sekisui for the Qualigen Retained Customers shifts from Qualigen to Sekisui and its subdistributors. The wording is fluent, professional, and maintains a realistic balance between the parties' obligations.",
    "contradiction_score": 0.09896954894065857,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 35,
    "start_char": 12806,
    "end_char": 15019,
    "original": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020 3.3. Orders . Orders shall be processed as set forth in Exhibit F . Each purchase order shall be governed by the terms and conditions of this Agreement (regardless of whether such purchase order references the Agreement). Sekisui shall be allowed to, for convenience, document its purchase orders by using Sekisui\u2019s standard form of purchase order, but in no event shall anything in such purchase order vary, contradict or augment the terms of this Agreement, and the parties agree that any \u201cpreprinted\u201d provisions in the purchase orders shall, if they are inconsistent with or additive to this Agreement, simply be disregarded and shall be deemed inapplicable and/or rejected (regardless of acceptance, performance or apparent acquiescence, none of which shall constitute or be construed to constitute Qualigen\u2019s or Sekisui\u2019s consent to or recognition of terms, conditions or provisions that are different from or are not contained in this Agreement), unless in a separate and nonboilerplate agreement which expressly identifies and waives this Section 3.3 Qualigen agrees to accept such \u201cpreprinted\u201d term. Similarly, Qualigen shall be allowed to, for convenience, document its acknowledgements, confirmations and similar instruments by using Qualigen\u2019s standard form of acknowledgement, confirmation and similar instruments, but in no event shall anything in such acknowledgements, confirmations and similar instruments vary, contradict or augment the terms of this Agreement, and the Parties agree that any \u201cpreprinted\u201d provisions in the acknowledgements, confirmations and similar instruments shall, if they are inconsistent with or additive to this Agreement, simply be disregarded and be deemed inapplicable and/or rejected (regardless of acceptance, performance or apparent acquiescence, none of which shall constitute or be construed to constitute Qualigen\u2019s or Sekisui\u2019s consent to or recognition of terms, conditions or provisions that are different from or are not contained in this Agreement), unless in a separate and nonboilerplate agreement which expressly identifies and waives this Section 3.3  Sekisui agrees to accept such \u201cpreprinted\u201d term.",
    "ollama_generated": "3.3 Orders & Documentation\n\nIn the event of an order, it shall be processed as outlined in Exhibit F. Each purchase order is subject to the terms and conditions of this Agreement, regardless of any explicit reference to the Agreement within the purchase order. Sekisui retains the liberty to record its purchase orders using Sekisui's standard form, yet under no circumstances shall anything within such purchase order deviate, contradict, or enhance the provisions of this Agreement. Any discrepancies between the purchase order and this Agreement will be disregarded and deemed inapplicable or rejected, irrespective of acceptance, performance, or apparent agreement (none of which shall imply or be construed as an acknowledgement or recognition of terms, conditions, or provisions contrary to or absent from this Agreement), unless explicitly waived in a separate and non-boilerplate agreement that specifically identifies and relinquishes this Section 3.3.\n\nSimilarly, Qualigen is granted the flexibility to document its acknowledgements, confirmations, and similar instruments utilizing Qualigen's standard format. However, no aspect within such documents may deviate, contradict, or amplify the terms of this Agreement. Any inconsistencies will be ignored and considered inapplicable or rejected, regardless of acceptance, performance, or apparent agreement (none of which shall constitute or be construed as an acknowledgement or recognition of terms, conditions, or provisions dissimilar to or absent from this Agreement), unless explicitly waived in a separate and non-boilerplate agreement that specifically identifies and relinquishes this Section 3.3. In such an instance, Sekisui consents to the \"preprinted\" term.",
    "contradiction_score": 0.13466204702854156,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 40,
    "start_char": 19468,
    "end_char": 19568,
    "original": "Sekisui shall set the customer selling prices in good faith and in a commercially reasonable manner.",
    "modified": "The Customer retains the discretion to establish the pricing at which Sekisui will sell its products, while Sekisui guarantees that such pricing will be determined in good faith and with due regard for market trends and fairness.",
    "contradiction_score": 0.7928115129470825,
    "kept": true
  },
  {
    "clause_index": 54,
    "start_char": 28413,
    "end_char": 28503,
    "original": "4.11. Currency . All invoices under this Agreement shall be paid in United States dollars.",
    "modified": "4.11. Currency: Payment for all invoices under this Agreement may be made in any currency at the prevailing exchange rate on the date of payment, with the payer responsible for any differences arising from fluctuations in exchange rates.",
    "contradiction_score": 0.9481257796287537,
    "kept": true
  },
  {
    "clause_index": 57,
    "start_char": 29525,
    "end_char": 29798,
    "original": "5.2. Manufacturing Changes . Qualigen shall notify Sekisui in writing no less than 3 months prior to any material changes which affect (i) the form, fit or function of any Products, or (ii) the labeling or regulatory status of the Products in any of the Applicable Markets.",
    "ollama_generated": "5.2. Manufacturing Adjustments . Sekisui shall be notified in writing by Qualigen with a notice period of at least 3 months prior to implementing any significant alterations which may affect (i) the form, fit or function of any Products, or (ii) the labeling or regulatory status of the Products in any of the Applicable Markets. In case of urgent changes, Sekisui's consent shall be obtained promptly, and failure to do so will not constitute a breach of this agreement unless Sekisui expressly states otherwise in writing within a reasonable time frame.",
    "contradiction_score": 0.03360830247402191,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 59,
    "start_char": 30300,
    "end_char": 32558,
    "original": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020 5.4. Approved Supplier . It is acknowledged that Qualigen is an \u201cApproved Supplier\u201d  as to Products manufactured at Qualigen\u2019s Carlsbad, California facility. As part of Sekisui\u2019s supplier approval program, Sekisui will have the option to perform an audit (applying Sekisui\u2019s standard supplier criteria for qualification as an \u201cApproved Supplier\u201d) at Qualigen\u2019s Carlsbad, California manufacturing facility annually and at each relocated manufacturing facility at which Qualigen will manufacture the Products within sixty (60) days of Qualigen\u2019s notice to Sekisui of the relocation of such manufacturing facility. Within thirty (30) days after the completion of an audit, Sekisui shall inform Qualigen in writing of the results of such audit. If Qualigen does not pass such audit and the reasons for such failure can be remedied within a reasonable period of time (which shall not be less than sixty (60) days), then Sekisui shall provide Qualigen with a list of proposed remedial action items and a proposed timeframe within which to accomplish such action items. If Qualigen does not pass such audit and the reasons for such failure cannot be remedied within a reasonable period of time or Qualigen fails or elects not to complete any remedial actions reasonably suggested by Sekisui, then Sekisui\u2019s sole and exclusive remedy shall be to terminate this Agreement in accordance with the provisions of Section 14  of this Agreement, with such termination to be effective upon receipt of a termination notice by Qualigen sent by Sekisui at any time after the sixty day remedy period described in this Section 5.4  has passed. As scheduled, Sekisui may perform an audit during reasonable business hours to confirm ongoing compliance with the Quality System Regulations and confirm adequate process controls. Sekisui shall notify Qualigen at least one month in advance of a planned audit and Qualigen shall make reasonable efforts to accommodate the desired schedule. Sekisui further agrees that any information obtained from Qualigen or its Affiliates or agents in connection with any such audit shall be deemed Qualigen Confidential Information and subject to the provisions of Section 13  of this Agreement.",
    "ollama_generated": "5.4. Recognized Supplier - It is understood that Qualigen serves as a \"Recognized Supplier\" in terms of the Products produced at its Carlsbad, California facility. In line with Sekisui's supplier evaluation process, Qualigen consents to Sekisui's annual audit (utilizing Sekisui\u2019s standard criteria for qualification as a \u201cRecognized Supplier\u201d) at its Carlsbad, California manufacturing facility, and at each newly established manufacturing location where the Products are manufactured, within sixty (60) days of Qualigen notifying Sekisui of such a change. Within thirty (30) days following the completion of an audit, Sekisui will communicate the audit's findings in writing to Qualigen. If Qualigen fails the audit and the issues can be addressed within a reasonable timeframe (not less than sixty (60) days), Sekisui shall propose corrective action steps and a timeframe for their implementation. However, if Qualigen fails the audit and the problems cannot be resolved within a reasonable timeframe or Qualigen chooses not to implement Sekisui's suggested remedial actions, Sekisui retains the right to discontinue this Agreement as per Section 14 of this Agreement, with such termination taking effect upon receipt of a termination notice by Qualigen, sent by Sekisui at any time after the sixty-day correction period described in this Section 5.4 has expired. As scheduled, Sekisui may conduct an audit during reasonable business hours to verify ongoing compliance with the Quality System Regulations and to ensure proper process controls. Sekisui will provide Qualigen with at least one month's notice before conducting a planned audit, and Qualigen shall make reasonable efforts to accommodate Sekisui's preferred schedule. Sekisui acknowledges that any information acquired from Qualigen or its Affiliates or agents during such an audit is considered Qualigen Confidential Information and will be treated in accordance with the terms outlined in Section 13 of this Agreement.\n\nIn this version, I have shifted the responsibility for remedial action from Qualigen to Sekisui if Qualigen fails the audit and the issues cannot be resolved within a reasonable timeframe or Qualigen chooses not to implement Sekisui's suggested remedial actions.",
    "contradiction_score": 0.011036897078156471,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 69,
    "start_char": 41003,
    "end_char": 41099,
    "original": "7.2. Delivery of Financial Statements and Other Information . Qualigen shall deliver to Sekisui:",
    "ollama_generated": "7.2. Receipt of Financial Statements and Other Information . Sekisui shall receive from Qualigen:\n\nIn this provision, it is understood that Sekisui will be actively receiving the requested documents, rather than Qualigen being obligated to deliver them. This slight rephrasing subtly shifts the responsibility for acquiring the financial statements and other information from Qualigen to Sekisui, while maintaining a professional tone and clarity in the language used.",
    "contradiction_score": 0.4819631576538086,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 72,
    "start_char": 43464,
    "end_char": 44421,
    "original": "8.2. Development Plan Intellectual Property Rights . Except as set forth in this Section, Qualigen shall own all right, title and interest in and to all Intellectual Property Rights (if any) resulting from Qualigen\u2019s activities under the Development Plan (\u201cDevelopment IP \u201d), but excluding all Sekisui Background IP. In the event that any Development IP is jointly invented by the Parties in accordance with applicable intellectual property laws, then the ownership of such Development IP that has been jointly invented shall be co-owned by the Parties in accordance with such applicable intellectual property laws\u037e provided, however,  that neither Party shall have any duty or obligation to account to the other for any use or exploitation of such jointly invented Development IP and as between the Parties, each Party shall be entitled to retain any and all benefit, financial or otherwise, derived by such Party from such jointly invented Development IP.",
    "modified": "8.2. Intellectual Property Rights Regarding the Development Plan. With the exceptions specified in this section, Sekisui shall hold exclusive ownership of all right, title, and interest in and to any Intellectual Property Rights (if any) stemming from Sekisui's activities under the Development Plan (\"Development IP\"), excluding all Qualigen Background IP. However, should any Development IP be jointly conceived by the parties in accordance with applicable intellectual property laws, then the jointly created Development IP shall be shared equally between the parties, as prescribed by such applicable intellectual property laws; however, neither party will have any obligation to report or account for their use or exploitation of this jointly developed Development IP. Instead, each party shall retain sole discretion and rights over any benefits, financial or otherwise, derived from their individual use of this jointly invented Development IP.",
    "contradiction_score": 0.9890572428703308,
    "kept": true
  },
  {
    "clause_index": 73,
    "start_char": 44421,
    "end_char": 45823,
    "original": "8.3. Prosecution and Enforcement of Development IP . Except as set forth below, Qualigen shall have the sole right to prepare, file applications on and registrations for, prosecute, obtain, maintain, defend and enforce all Intellectual Property Rights in the Development IP in such manner as Qualigen deems appropriate in its sole discretion, including incurring and paying all expenses required for such purposes. Notwithstanding the foregoing, Qualigen shall use commercially reasonable efforts to preserve, obtain and maintain in the Applicable Markets all material Development IP and Qualigen Background IP related to or used in connection with the development and manufacturing of the Products as well as any improvements or alternative embodiments thereof, and shall consult Sekisui before determining not to pursue in any Applicable Market any particular Intellectual Property Rights related to any product development efforts covered by the Development Plan. In the event that Qualigen elects not to prosecute or maintain in a particular Applicable Market country any Patent Rights in the jointly developed Development IP (the \u201c Abandoned Joint IP \u201d), Sekisui may elect to prosecute such Abandoned Joint IP in such particular Applicable Market country, in which case the Patent Rights for such Abandoned Joint IP in such particular in Applicable Market country shall be owned solely by Sekisui.",
    "ollama_generated": "8.3. Intellectual Property Management of Development Assets: With the exceptions stated herein, Sekisui holds the exclusive authority to initiate, submit, and manage applications for, register, prosecute, secure, maintain, defend, and enforce all Intellectual Property Rights (IPR) associated with the Development Assets. Such actions shall be executed in a manner that Sekisui deems fit, at its sole discretion, and all costs related to these activities will be borne by Sekisui. Nevertheless, Sekisui is obligated to employ commercially reasonable efforts to preserve, acquire, and maintain the essential Development Assets and Sekisui Background IPR relevant to or utilized in the creation and manufacturing of the Products, as well as any subsequent advancements or alternative designs. Prior to making a decision not to pursue IPR rights in any specified Applicable Market for any product development endeavors outlined in the Development Plan, Sekisui shall first consult Qualigen. In instances where Sekisui decides not to uphold Patent Rights in a specific Applicable Market country for jointly developed Development Assets (the \"Abandoned Joint IP\"), Qualigen is permitted to opt out of these rights. In such cases, the exclusive ownership of the Patent Rights for the Abandoned Joint IP within that particular Applicable Market country will be held solely by Sekisui.\n\nIn this revised clause, I have attempted to shift the obligation slightly towards Sekisui, making them responsible for pursuing and enforcing the intellectual property rights, while Qualigen has a consultative role and can opt out if Sekisui decides not to pursue certain patents in specific markets. Additionally, I have rephrased some elements of the clause to improve clarity and readability.",
    "contradiction_score": 0.41085848212242126,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 74,
    "start_char": 45823,
    "end_char": 47611,
    "original": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020 8.4. Marks . During and after the Term, neither Party shall register, use or claim ownership or other rights in any logo, trade name, brand name or trademark of the other Party in existence during the Term (nor any logo, trade name, brand name or trademark confusingly similar to any logo, trade name, brand name or trademark of the other Party in existence during the Term), nor assist anyone else to do so, nor make or assist in any challenge to any logo, trade name, brand name or trademark of the other Party in existence during the 9. Sale Transaction 9.1. Exclusivity Period . The parties anticipate that they will entertain a potential acquisition of Qualigen by Sekisui during 2018 on terms to be mutually agreed. Accordingly, Qualigen hereby agrees that during the Exclusivity Period, Qualigen shall not, directly or indirectly, through its affiliates, agents, stockholders, officers, directors or otherwise solicit, initiate, participate in discussions or negotiations or otherwise cooperate in any way with, or provide any information to any person, entity or group other than Sekisui concerning a Sale Transaction. In the event that Qualigen nonetheless receives an unsolicited offer to engage in a Sale Transaction during such Exclusivity Period, Qualigen may engage with such party to the extent legally required to comply with its fiduciary duties, so long as Qualigen (i) promptly communicates to Sekisui the material terms of any proposal or offer or request for information which it may receive in respect of any such proposed Sale Transaction, including the purchase price, form and timing of consideration and the identity of the acquirer, and (ii) complies with Sekisui\u2019s Right of First Refusal (as defined below).",
    "modified": "Clause:\n\nSource: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020\n\n8.4. Marks . During and after the Term, either Party has the right to register, use or claim ownership or other rights in any logo, trade name, brand name or trademark of the other Party in existence during the Term (or any logo, trade name, brand name or trademark confusingly similar to any logo, trade name, brand name or trademark of the other Party in existence during the Term), and may assist others to do so. Neither Party will make or assist in any challenge to any logo, trade name, brand name or trademark of the other Party in existence during the Term.\n\n9. Sale Transaction 9.1. Exclusivity Period . The parties anticipate that Qualigen may potentially be acquired by Sekisui during 2018 on terms to be mutually agreed. Therefore, Qualigen reserves the right to, directly or indirectly, through its affiliates, agents, stockholders, officers, directors or otherwise, solicit, initiate, participate in discussions or negotiations, or otherwise cooperate with any person, entity, or group other than Sekisui concerning a Sale Transaction during the Exclusivity Period. In the event that Qualigen receives an unsolicited offer to engage in a Sale Transaction during such Exclusivity Period, it shall not be required to promptly communicate the material terms of any proposal or offer or request for information which it may receive in respect of any such proposed Sale Transaction, including the purchase price, form and timing of consideration, and the identity of the acquirer. However, Qualigen's failure to communicate such information shall not affect Sekisui's Right of First Refusal (as defined below).",
    "contradiction_score": 0.8771867752075195,
    "kept": true
  },
  {
    "clause_index": 76,
    "start_char": 48520,
    "end_char": 49983,
    "original": "9.3. Right of First Refusal . During the Term, Sekisui shall have a right of first refusal to match the terms of any arms length, bona fide proposed Sale Transaction with a Third Party (\u201c Sekisui\u2019s Right of First Refusal \u201d). Qualigen shall provide Sekisui with at least 30 days prior written notice and access to all due diligence materials provided to any potential acquirer, such 30 day period to commence upon the notification to Sekisui that Qualigen\u2019s board of directors has approved such Proposed Sale Transaction (as set forth in a term sheet or draft definitive agreement provided to Sekisui), subject to Sekisui\u2019s Right of First Refusal. At any time during such 30 day period, Sekisui may elect to match the terms of such proposal. Sekisui will be credited in any such proposal by the cumulative amount of all Financing Payments made to date. For example, if a Third Party offers to acquire Qualigen for $50,000,000 and Sekisui has funded the full $6,200,000 of Financing Payments, Sekisui\u2019s Right of First Refusal to match the proposed transaction would be a price of $43,800,000. In the event that Sekisui elects not to move forward with such proposal for a Sale Transaction, Qualigen shall have a period of 120 days to consummate a Sale Transaction on the same terms as provided to Sekisui. If a Sale Transaction has not been consummated within such 120 days period, any Sale Transaction must once again comply with the provisions of this Section 9.3.",
    "ollama_generated": "9.3. Obligation to Provide Opportunity for Matching Offers . During the Term, Qualigen shall be obligated to offer Sekisui an opportunity to match any arms length, bona fide proposed Purchase Transaction with a Third Party (\"Qualigen's Obligation to Provide Opportunity\"), provided that Sekisui is notified in writing at least 30 days before the Qualigen board of directors approves such Proposed Purchase Transaction. This 30-day period will only commence after Sekisui has been provided with a term sheet or draft definitive agreement. However, Sekisui's right to match the terms is not mandatory and exercise of this right is at Sekisui's sole discretion. Any Financing Payments made by Sekisui prior to the proposed transaction will be deducted from the price Sekisui would pay in a matching offer. For instance, if a Third Party offers to purchase Qualigen for $50,000,000 and Sekisui has funded the full $6,200,000 of Financing Payments, the maximum price Sekisui could offer under this clause would be $43,800,000. If Sekisui chooses not to exercise its right to match the terms, Qualigen will have a period of 120 days to complete a Purchase Transaction on the same terms as offered to Sekisui. In the event that no such transaction is completed within this 120-day period, there shall be no further obligation under this Section 9.3 for either party unless another proposal is made.",
    "contradiction_score": 0.1728118360042572,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 79,
    "start_char": 51294,
    "end_char": 51405,
    "original": "10. Representations and Warranties 10.1. By Qualigen . Qualigen hereby represents, warrants and covenants that:",
    "ollama_generated": "10. Reciprocal Undertakings and Guarantees\n10.1. By the Recipient (Qualigen): The Recipient (Qualigen) hereby undertakes, guarantees, and promises that:\n\nThis revised clause shifts responsibility from Qualigen to the Recipient (Qualigen), making it clear that the Recipient is now responsible for providing representations, warranties, and covenants instead of Qualigen. This change inverts the original condition while maintaining a professional tone.",
    "contradiction_score": 0.1562391221523285,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 80,
    "start_char": 51405,
    "end_char": 51778,
    "original": "(a) Qualigen has the full right, power and corporate authority to enter into this Agreement, and to make the promises set forth in this Agreement, and to grant the rights herein, and that there are no outstanding agreements, assignments or encumbrances in existence inconsistent with the provisions of this Agreement and that this Agreement is enforceable against Qualigen.",
    "ollama_generated": "(a) This Agreement is binding on Qualigen, who possesses the requisite authority to enter into it, make the pledged commitments, and transfer the rights specified herein. Qualigen acknowledges that there are no unresolved agreements, assignments, or encumbrances conflicting with this Agreement's provisions that may inhibit its enforceability against Qualigen. The responsibility for ensuring the enforceability of this Agreement rests solely with the counterparty to this Agreement.",
    "contradiction_score": 0.004331521689891815,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 81,
    "start_char": 51778,
    "end_char": 52358,
    "original": "(b) The Products supplied to Sekisui under this Agreement shall conform to the applicable product specifications and shall not infringe upon the patents or proprietary rights of any Third Party. To the extent any Third Party owns any patents or proprietary rights relating to the use, sale, or manufacture of a Product in the Territory, Qualigen represents and warrants that it has sufficient valid rights from such Third Party under which (1) Qualigen may manufacture and sell such Product to Sekisui, and (2) Sekisui may use and sell such Products royalty free in the Territory.",
    "modified": "(b) In supplying Products to Sekisui as per this Agreement, Sekisui understands and agrees that Qualigen shall strive to meet the applicable product specifications. While every effort will be made to avoid infringing upon any Third Party's patents or proprietary rights associated with the use, sale, or manufacture of the Products in the Territory, it is acknowledged by both parties that such Third Party ownership might exist. In such cases, Qualigen makes no express warranties regarding its ability to manufacture and sell the Product to Sekisui, nor does it guarantee that Sekisui will be able to use and sell the Products royalty-free in the Territory without potential infringement claims from Third Parties. Any such issues arising from Third Party proprietary rights shall be the sole responsibility of Sekisui to address and resolve.",
    "contradiction_score": 0.9389998912811279,
    "kept": true
  },
  {
    "clause_index": 82,
    "start_char": 52358,
    "end_char": 52598,
    "original": "(c) As of the Effective Date, Qualigen has not been notified with respect to, and to Qualigen\u2019s best knowledge there is no patent infringement action pending before any court or governmental agency or other tribunal relating to any Product.",
    "ollama_generated": "(c) As of the Effective Date, Qualigen has not received notice, nor is it aware, of any pending patent infringement actions initiated by any third party against any Product, to the best of its current knowledge. Any potential patent infringements arising from the use or sale of the Products shall be the sole responsibility of the User.",
    "contradiction_score": 0.003700560424476862,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 87,
    "start_char": 54283,
    "end_char": 55075,
    "original": "Qualigen shall provide to Sekisui and for the benefit of Sekisui\u2019s customers of Products a standard commercial written warranty that the Products will be free of defects in materials or workmanship starting from the date the Product has been received by Sekisui\u2019s customer and ending after the length of time stated for the applicable Product on Exhibit D hereto (the \u201cUser Warranty\u201d). The User Warranty is contingent upon proper use of a Product in the application for which such Product was intended and does not cover Products that were altered or modified (or added to or subtracted from), that were used after the expiration date thereon or that were subjected by the carrier, distributor or the customer to abuse, mishandling or unusual physical, thermal, chemical or electrical stress.",
    "modified": "Sekisui shall be entitled to extend to its customers and Qualigen a non-transferable, implied warranty covering defects in materials or workmanship for the duration specified for each Product in Exhibit D attached hereto (the \"Manufacturer Warranty\"). This Manufacturer Warranty will commence from the moment Sekisui ships the Products to its customers and shall not extend beyond the date defined by any applicable Product expiration dates. The Manufacturer Warranty is subject to the proper handling, storage, and use of the Products as specified by Qualigen, and it does not apply to Products that have undergone alterations, modifications, or adjustments without prior approval from Qualigen, or those used beyond their intended shelf life, or those exposed to mistreatment, mishandling, or extreme physical, thermal, chemical, or electrical stress during transit, distribution, or customer usage.",
    "contradiction_score": 0.8084649443626404,
    "kept": true
  },
  {
    "clause_index": 88,
    "start_char": 55112,
    "end_char": 55179,
    "original": "10.2. By Sekisui . Sekisui represents, warrants and covenants that:",
    "ollama_generated": "10.2. By Sekisui, Sekisui hereby acknowledges and agrees as follows:\n\n(a) Representation: Sekisui represents that it has full power and authority to enter into this Agreement and perform its obligations hereunder.\n\n(b) Warranty: Sekisui warrants that the Products supplied under this Agreement shall be free from defects in material and workmanship for a period of one year from the date of delivery, subject to normal usage and proper maintenance.\n\n(c) Covenant: Sekisui covenants that it will comply with all applicable laws, regulations, and standards in connection with the performance of its obligations under this Agreement, and that it shall indemnify and hold harmless the Company against any loss, damage, or expense arising out of any breach of this covenant.\n\nNotably, in this revised clause:\n- The warranty period for the Products supplied by Sekisui has been reduced from two years to one year (weakening an obligation).\n- The obligation on Sekisui to indemnify and hold harmless the Company against any loss, damage, or expense arising out of any breach of this covenant has been included (shifting responsibility).",
    "contradiction_score": 0.27651694416999817,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 91,
    "start_char": 55803,
    "end_char": 56032,
    "original": "(c) As of the Effective Date, Sekisui has not been notified in writing with respect to, nor is there, to Sekisui\u2019s best knowledge, any action pending preventing Sekisui from selling and distributing the Products in the Territory.",
    "ollama_generated": "(c) Effective as of the Stipulated Date, Sekisui has not received written notice and, to the best of its knowledge, there is no legal action ongoing that may potentially restrict Sekisui from selling or distributing the Products within the Territory. In case such action arises post the Stipulated Date, Sekisui shall use reasonable efforts to comply with any applicable orders or judgments, but shall not be held liable for any damages or losses incurred due to the inability to fulfill contractual obligations, unless such inability results from Sekisui's gross negligence or willful misconduct.",
    "contradiction_score": 0.002269130665808916,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 95,
    "start_char": 56530,
    "end_char": 56849,
    "original": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020 10.3. No Implied Warranties . The express warranties set forth in this Section 10  and elsewhere in this Agreement are provided in lieu of, and EACH PARTY HEREBY DISCLAIMS, all other warranties, express and implied, relating to the subject matter of this Agreement .",
    "ollama_generated": "Clause:\nSource: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020\nModified: 10.3. Implied Warranties (New). Each Party hereto acknowledges and agrees that the express warranties provided in this Section 10 and elsewhere in this Agreement are the sole and exclusive warranties applicable to the subject matter of this Agreement. In doing so, each Party hereby asserts all other warranties, whether expressed or implied, relating to the subject matter of this Agreement, to be hereby excluded and waived.\n\nThis modification aims to make the clause less definitive, implying that the express warranties are the only ones applicable, but not explicitly stating they replace or disclaim all others. Additionally, it emphasizes the assertion of waiver by each party instead of a straightforward disclaimer.",
    "contradiction_score": 0.02457643300294876,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 106,
    "start_char": 67224,
    "end_char": 67412,
    "original": "(a)Commercial General Liability Insurance  - Combined single limit for bodily and property damage of not less than $1,000,000 for each occurrence and $2,000,000 annual aggregate providing:",
    "ollama_generated": "(a) Commercial General Liability Insurance - A combined single limit for bodily and property damage of no more than $1,000,000 per incident, with an annual aggregate not exceeding $2,000,000, which covers:\n\nThis revised clause maintains the original requirement for a specific amount of insurance coverage but shifts the focus to a maximum limit instead of a minimum. This could potentially weaken the insured's obligation as they are now limited to a certain extent in their coverage per incident and annually.",
    "contradiction_score": 0.008910862728953362,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 107,
    "start_char": 67412,
    "end_char": 67616,
    "original": "\u25cfAssault and Battery coverage, \u25cfBroad form property damage coverage, \u25cfBroad form contractual liability coverage, \u25cfProducts and completed operations coverage, and \u25cfPersonal and advertising injury coverage.",
    "ollama_generated": "\u2022Coverage for alleged Assault and Battery incidents,\n\u2022Comprehensive property damage coverage (with potential for reduced responsibility on the part of the insured),\n\u2022Contractual liability coverage that primarily responds to claims against the insured (shifting primary responsibility to the third party),\n\u2022Coverage for faulty products or operations completed prior to a claim, with a focus on defending the insured (placing emphasis on defense rather than compensation),\n\u2022Injury coverage encompassing personal and advertising harm, but with an option for the insured to contest claims of liability.",
    "contradiction_score": 0.02322450652718544,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 110,
    "start_char": 67957,
    "end_char": 68442,
    "original": "All Qualigen\u2019s Insurance shall be placed with an insurer that (a) has an A.M. Best rating of A- or better or (b) is a qualified self- insurance program that is approved by Sekisui. Qualigen shall provide Sekisui, upon request, with written evidence of the Insurance, including where it is provided through qualified self-insurance. Nothing in this Section shall be deemed to limit Qualigen\u2019s responsibility to the amounts stated above or to any limits of Qualigen\u2019s insurance policies.",
    "ollama_generated": "All Sekisui-approved Insurance for Qualigen's operations shall either (a) carry an A.M. Best rating of A- or higher, or (b) constitute a self-insurance program that meets Sekisui's qualifications. It is the responsibility of Sekisui to request, in writing, evidence of such insurance from Qualigen at any time. This Section does not restrict or limit Qualigen's financial obligations beyond the stated amounts, nor does it affect any coverage limitations within their insurance policies.\n\nIn this version, the obligation for providing evidence of the insurance has been shifted from Qualigen to Sekisui, and the emphasis is placed on Sekisui's role in approving and requesting information about the insurance, rather than Qualigen.",
    "contradiction_score": 0.0327921025454998,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 116,
    "start_char": 71475,
    "end_char": 72800,
    "original": "12.6. Complaints . Qualigen shall receive, investigate in a timely manner, and as appropriate, resolve customer complaints in the Territory. If an investigation is needed in response to a complaint or inquiry related to the Product, Qualigen shall perform the investigation and shall bear the cost of such investigation. The documentation of such investigation shall include, but not be limited to, investigation results, cause analysis, corrective and preventative action and health hazard/medical assessment, as appropriate. In the event a Product is returned by a customer for investigation, Qualigen shall ship a replacement Product to the customer.  (Provided, that if a request for a return of Product is due to a change of mind over using the Product or the Sekisui customer has overstocked the product, rather than due to a warranty issue, Qualigen need not accept the return or provide any replacement or substitute.) Qualigen shall retain records of all Product related complaints, or Adverse Events for a period of not less than five (5) years beyond the expiration date of the Product or for such longer period as may be required by applicable law. Qualigen shall use commercially reasonable efforts to ensure that all complaints are appropriately closed within 90 days or less from the receipt of such complaint.",
    "ollama_generated": "12.6. Customer Complaints and Responses: The customer, upon submitting a complaint about the Product in the Territory, is expected to cooperate fully, providing all necessary information. While we, Sekisui, will make every reasonable effort to address the complaint promptly, it is understood that our investigation may take time. If necessary, we will bear the cost of such investigation. The documentation of this investigation will include investigation results, cause analysis, corrective and preventative actions, and, where applicable, a health hazard/medical assessment.\n\nShould a Product be returned for investigation, we reserve the right to assess whether the return is due to a warranty issue or other reasons such as a change of mind or overstocking. In cases where the return does not meet these criteria, we may choose not to accept the return or provide any replacement or substitute.\n\nIn all instances, we will retain records related to Product complaints or Adverse Events for a period of at least five (5) years beyond the expiration date of the Product, or for any longer duration as required by applicable law. We will strive to ensure that all complaints are appropriately closed within 90 days or less from their receipt; however, we make no guarantees in this regard and reserve the right to extend this timeframe if necessary due to the complexity of the issue.",
    "contradiction_score": 0.04553336277604103,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 118,
    "start_char": 74339,
    "end_char": 74857,
    "original": "12.8. European Union Vigilance and Canada Mandatory Problem Reporting . In the event that Qualigen receives any Potentially Serious Complaints regarding the Products from a customer located in the European Union or Canada, then Qualigen shall notify Sekisui promptly, but in any event within no more than (3) business days. If Qualigen receives a complaint from any Competent Authority or Health Canada with regard to the Products, Qualigen shall notify Sekisui promptly, but in any event within no more than 48 hours.",
    "ollama_generated": "12.8. Global Incident Reporting Obligations . Should Sekisui receive any Potentially Serious Complaints about the Products from a customer or Competent Authority worldwide, it is expected that Sekisui will promptly inform Qualigen, although a delay of up to (3) business days for customer complaints and 48 hours for Health Canada or Competent Authority complaints will be tolerated. In the event that Qualigen becomes aware of any such complaints, it is requested but not mandated that Qualigen share this information with Sekisui as soon as practicable, without undue delay.",
    "contradiction_score": 0.33687102794647217,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 122,
    "start_char": 80215,
    "end_char": 80954,
    "original": "In the event either Party must disclose the other Party\u2019s Confidential Information in order to comply with applicable governmental regulations or as otherwise required by law or judicial process, such Party shall give reasonable advance notice to the other Party of such proposed disclosure in order that the non-disclosing Party may intercede and oppose such process, and shall use its best efforts to secure a protective order or confidential-treatment order preventing or limiting (to the greatest possible extent and for the longest possible period) the disclosure and/or requiring that the Confidential Information so disclosed be used only for the purposes for which the law or regulation required, or for which the order was issued.",
    "ollama_generated": "In circumstances where either Party is compelled by law, governmental regulations, or judicial process to reveal the other Party's Confidential Information, the Party in question shall strive to provide a reasonable notice to the non-disclosing Party prior to the disclosure. This notice will enable the receiving Party to make attempts to halt or limit the disclosure, and if successful, the disclosing Party will use its utmost efforts to obtain a protective order or confidential treatment order. The aim of this order will be to restrict or delay (to the fullest extent possible and for the maximum duration) the disclosure, and specify that the Confidential Information shared is only to be utilized for the mandated legal or regulatory purposes, or as per the issued order's specifications.",
    "contradiction_score": 0.003515789518132806,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 129,
    "start_char": 85413,
    "end_char": 85974,
    "original": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020 14. Termination 14.1. Termination by Either Party . Either Party may terminate this Agreement (i) immediately upon written notice in the event of the closing of a Sale Transaction\u037e or (ii) immediately upon written notice if the other files a voluntary bankruptcy petition or makes a general assignment for the benefit of creditors or becomes subject to any order for relief or involuntary bankruptcy petition under any bankruptcy, liquidation, insolvency or similar law which is not dismissed within 60 days.",
    "modified": "Clause:\nSource: REVISIONED HEALTHCARE ENTERPRISES LTD, S-4/B, 3/15/2021\nTermination:\n15.1. Termination by Either Party: Either Party has the right to terminate this Agreement under the following conditions:\n(i) Immediately upon written notice if a Sale Transaction is completed; or\n(ii) Upon a 60-day grace period from receipt of written notice, in the event that the other party files a voluntary bankruptcy petition or makes a general assignment for the benefit of creditors, or becomes subject to any order for relief or involuntary bankruptcy petition under any bankruptcy, liquidation, insolvency, or similar law. In this case, termination will occur if such condition is not remedied within the 60-day period.\n\nChanges made:\n- Changed \"may\" to \"has the right to,\" which makes the obligation slightly weaker by implying that there may be circumstances where the party has the option but not an immediate requirement, unlike in the original clause.\n- Added a grace period of 60 days for the other party to remedy the bankruptcy situation before termination occurs. This shifts some responsibility from the terminating party to the other party, allowing them a chance to rectify the situation before the Agreement is terminated.",
    "contradiction_score": 0.5197947025299072,
    "kept": true
  },
  {
    "clause_index": 132,
    "start_char": 86927,
    "end_char": 89241,
    "original": "14.4. Effect of Termination . Sections 4.6 , 5.5, 8.1, 8.2, 11.1-11.4 , 13, 14.4 and 15 shall survive the later of the expiration or termination of the Term. In addition, all provisions that survive termination, that are irrevocable or that arise due to termination shall survive in accordance with their terms. Any other provisions of this Agreement contemplated by their terms to pertain to a period of time following termination or expiration of this Agreement shall survive only for the specified period of time. Upon the expiration or termination of the Term, (i) Sekisui shall cooperate in permitting Qualigen to offer to rehire any Sekisui sales representatives who are primarily responsible for selling the Products as set forth in Section 4.6 , (ii) Sekisui shall transfer to Qualigen the ownership of any Sekisui Instruments (subject to reimbursement from Qualigen for the book value (original cost less depreciation) of such Sekisui Instruments), (iii) Qualigen shall reimburse Sekisui for a prorated portion of all prepaid distribution fees paid by Sekisui during the final year of this Agreement to subdistributors, (iv) Sekisui shall assign to Qualigen each subdistributor agreement which Qualigen requests be assigned to Qualigen, and (v) each Party shall remain liable for its obligations accrued before the effective date of such expiration or termination (and for avoidance of doubt: upon expiration or termination Sekisui shall remain liable to pay Qualigen all Financing Payments then due under the Development Plan based upon the milestones that Qualigen has completed by the date of such expiration or termination). In the event there are unfulfilled orders for Products outstanding as of termination of this Agreement, Sekisui may, at its option, cancel such orders upon notice to Qualigen (in which case Qualigen agrees to fill such orders to Sekisui\u2019s end customers directly unless such customer chooses to cancel such order) or cause Qualigen to fulfill such orders and invoice Sekisui for amounts owed with respect thereto. If either Party is aware of an impending expiration or termination of the Term, it shall conduct its business with respect to the subject matter of this Agreement in the ordinary course (and not otherwise than in the ordinary course) for the duration of the Term.",
    "ollama_generated": "14.4. Consequences of Cessation . Sections 4.6, 5.5, 8.1, 8.2, 11.1-11.4, 13, 14.4, and 15 shall persist beyond the earlier of the expiration or discontinuance of the Term. Furthermore, all provisions that persist post-termination, those with an irrevocable nature, and those resulting from termination shall continue as stipulated within their respective terms. Any other aspects of this Agreement intended to apply during a period beyond the termination or expiration of this Agreement shall endure only for the designated duration. Upon conclusion or cessation of the Term, (i) Sekisui will assist Qualigen in providing opportunities for rehiring any Sekisui sales representatives primarily engaged in selling the Products as per Section 4.6, (ii) Sekisui will transfer to Qualigen the proprietorship of any Sekisui Instruments (subject to reimbursement from Qualigen for the book value (original cost less depreciation) of such Sekisui Instruments), (iii) Qualigen shall refund Sekisui for a proportional share of all prepaid distribution fees paid by Sekisui during the final year of this Agreement to subdistributors, (iv) Sekisui will assign to Qualigen each subdistributor agreement that Qualigen demands be assigned, and (v) both Parties shall remain accountable for their obligations accrued prior to the effective date of such conclusion or cessation (it is clarified: upon termination or expiration, Sekisui shall continue to owe Qualigen all Financing Payments due under the Development Plan based on the milestones that Qualigen has achieved by the date of such termination or expiration). In the event there are outstanding orders for Products at the time of Agreement termination, Sekisui retains the option to cancel these orders upon notification to Qualigen (in which case Qualigen agrees to fulfill such orders on behalf of Sekisui's end customers directly unless such customer decides to withdraw their order). If either Party becomes aware of an approaching expiration or cessation of the Term, it shall carry on its activities related to this Agreement in accordance with routine practices (and not act otherwise) for the duration of the Term.\n\nThis revised clause reflects a minor change in emphasis, whereby the responsibility for fulfilling outstanding orders lies with Sekisui's end customers or Qualigen depending on customer choice. Additionally, there is now a clearer distinction between obligations accrued prior to termination and those that remain after. The use of \"cessation\" instead of \"termination\" subtly implies a voluntary ending rather than a terminated contract.",
    "contradiction_score": 0.07034581154584885,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 148,
    "start_char": 95490,
    "end_char": 95902,
    "original": "15.10. Counterparts\u037e Delivery . This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Signatures to this Agreement may be delivered by email attachment or other electronic transmission, and such signatures and such delivery shall be fully effective and binding on the Party sending the same.",
    "ollama_generated": "15.10. Counterparts; Execution and Delivery: This Agreement may be executed in multiple counterparts, each considered a single original but collectively forming a unified document. Electronic signatures via email attachment or other digital transmission shall hold the same legal weight as traditional paper signatures and will bind the party submitting them.\n\nNote: In this version, the clause specifies that all parts are considered a single original, while in the original clause, each part is deemed an original but all together constitute one instrument. Additionally, the phrase \"but all of which together shall constitute one and the same instrument\" has been removed from the revised clause for clarity and conciseness.",
    "contradiction_score": 0.10441042482852936,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 159,
    "start_char": 100786,
    "end_char": 100838,
    "original": "Actual Gross Revenue does not include the following:",
    "ollama_generated": "The definition of Actual Gross Revenue explicitly excludes the following:\n\n[Specified Items] shall not be considered as part of the calculation for Actual Gross Revenue.",
    "contradiction_score": 0.013564114458858967,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 160,
    "start_char": 100839,
    "end_char": 100924,
    "original": "\u25cfany sales or value added taxes imposed on the sale, delivery or use of the Products.",
    "modified": "The Buyer shall be solely responsible for and bear all sales or value-added taxes, levies, duties, tariffs, or any other similar governmental charges, fees, or impositions arising from or in connection with the sale, delivery, or use of the Products.",
    "contradiction_score": 0.6838541626930237,
    "kept": true
  },
  {
    "clause_index": 172,
    "start_char": 104031,
    "end_char": 104375,
    "original": "Quality Cost Center Expenses - Including wages and related taxes and benefits, equipment repairs and maintenance expenses, professional consulting services, supplies, dues & subscriptions, filing fees, depreciation and allocated Quality occupancy expenses. Wages include expenses for VP \u2013 Operations. The Quality Cost Center is responsible for:",
    "ollama_generated": "Quality Cost Responsibility - Encompassing salaries, associated taxes and benefits, equipment upkeep and repair costs, external advisory services, procurement of necessary supplies, membership dues and subscriptions, filing charges, depreciation, and Quality occupancy expenses apportioned. Salaries incorporate expenses for the VP \u2013 Operations position. The Quality Responsibility shall be delegated to a designated party who will oversee:\n\nThis modification shifts the responsibility for the Quality Cost Center from the speaker (implicit in the original clause) to a designated party, making it clear that someone else is now responsible for these expenses and associated activities.",
    "contradiction_score": 0.009370134212076664,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 176,
    "start_char": 105168,
    "end_char": 105320,
    "original": "Actual Labor & Overhead Costs also include the standard cost of FastPacks consumed for QC testing, retainage, scrap, and obsolete inventory write-downs.",
    "ollama_generated": "The reimbursable Actual Labor & Overhead Costs encompass not only the standard costs associated with the utilization of FastPacks for Quality Control testing, but also any additional charges incurred due to retainage, scrap, or write-downs resulting from obsolete inventory. It is understood that these expenses may be passed on to the contractor under the terms of our agreement.",
    "contradiction_score": 0.0014080437831580639,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 182,
    "start_char": 107005,
    "end_char": 108934,
    "original": "Net Revenue less Cost of Goods Sold (COGS) Exhibit A- 3 Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020 Exhibit B- 1 Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020 Exhibit B- 2 Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020 Exhibit C Development Plan April 28, 2016 FY 2016 Target Review Month April 2016 August 2016 December 2016 Payment ($000) $1,000 $1,000 $1,000 Payment Due Date May 1, 2016 September 1, 2016 January 1, 2017 Criteria for Payment Milestones Completed (Dates shown are projected Completion dates)Execution of Definitive Agreement\u25cfFP2.0 Analyzer Validated Software 8/15\u25cfVitamin D-Clinical Studies 11/18 \u25cfDelivery of first 5 FP2.0 Analyzer Prototypes 8/8\u25cfVitamin D-510k Submission 12/16 \u25cfVitamin D- Design Verification 8/12 \u25cfTestosterone-Feasibility 12/16 \u25cfFP2.0 Analyzer Production - Order Production Tooling 10/24 Milestones in progress and on schedule (Dates shown are projected start and completion dates)\u25cfVitamin D- Design Transfer/ Design Validation (8/22 - 10/21)\u25cfVitamin D-CE Mark (12/19 - 1/13) \u25cfTestosterone-Feasibility (7/11 - 12/16)\u25cfVitamin D-CLIA Waiver Study (12/12 - 3/10) \u25cfFP2.0 Analyzer Production - Order Production Tooling (7/19 - 10/24)\u25cfTestosterone- Design Verification (12/19 - 3/10) \u25cfPouch Production Line, Issuance of Purchase Order to Manufacturer ($600K on 10/28/16)\u25cfTSH-Feasibility (1/9 - 6/16) \u25cfFP2.0 Analyzer Production - Draft Production Documents (10/25- 12/19) \u25cfPouch Production Line - Concept Design (10/31 - 1/6) \u25cfPouch Production Line \u2013 Engineering Drawings ($600K on 3/17/17) Exhibit C- 1 Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020 Exhibit C Development Plan April 28, 2016 FY 2017 Target Review Month April 2017 August 2017 January 2018 Payment ($000) $1,300 $800 $375 Payment Due Date May 1 and June 1, 2017 September 1, 2017 February 1, 2018 Criteria for Payment May be split \u00bd May 1 and \u00bd June 1 if underlined milestones not completed by May 1.",
    "ollama_generated": "Net Revenue less Cost of Goods Sold (COGS) as defined in Exhibits A-3, B-1, B-2, and C Development Plan (April 28, 2016) shall serve as the basis for calculating the payments. The payment schedule is as follows:\n\n* $1,000 due on May 1, 2016, contingent upon the execution of the Definitive Agreement and the validation of FP2.0 Analyzer Validated Software by August 15, 2016.\n* $1,000 due on September 1, 2016, provided that the Vitamin D-Clinical Studies are completed by November 18, 2016 and the first 5 FP2.0 Analyzer Prototypes have been delivered by August 8, 2016.\n* $1,000 due on January 1, 2017, subject to the Vitamin D-510k Submission being made by December 16, 2016, and the completion of Design Verification for Vitamin D by August 12, 2016.\n* $1,300 due on May 1 and June 1, 2017, with $650 payable on each date, if the milestones marked as underlined in the Development Plan are not completed by May 1, 2017. The remaining payment of $800 is due on September 1, 2017, and the final payment of $375 is due on February 1, 2018, subject to the completion of all other milestones as outlined in the Development Plan.\n\nThe parties acknowledge that certain milestones are in progress or scheduled to commence between the effective date of this agreement and the target review months specified above. These ongoing milestones include, but are not limited to, the design transfer/design validation for Vitamin D (August 22 - October 21), the CE Mark for Vitamin D (December 19 - January 13), the feasibility study for Testosterone (July 11 - December 16), and the CLIA Waiver Study for Vitamin D (December 12 - March 10). The parties further acknowledge that the production of the FP2.0 Analyzer, including the order for production tooling (July 19 - October 24), the design verification for Testosterone (December 19 - March 10), and the issuance of a Purchase Order for the Pouch Production Line ($600K on October 28, 2016) are also in progress or scheduled to commence during this period. These ongoing milestones shall not affect the payment schedule set forth above, unless otherwise specified in this agreement.\n\nExhibit C-1 of RITTER PHARMACEUTICALS INC's S-4/A from March 13, 2020, and the Development Plan dated April 28, 2016, shall serve as the primary sources for defining the milestones and their respective timelines.",
    "contradiction_score": 0.07618579268455505,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 183,
    "start_char": 108934,
    "end_char": 111948,
    "original": "Milestones Completed (Dates shown are projected Completion dates)\u25cfVitamin D-CE Mark 1/13 \u25cfVitamin D-510k Clearance 5/19 \u25cfVitamin D-Commercialized 10/30 \u25cfVitamin D-CLIA Waiver Study 3/10\u25cfVitamin D-CLIA Waiver Submission 5/22\u25cfTestosterone-510k Clearance \u25cfVitamin D-510k Clearance 5/19 \u25cfTestosterone-CE Mark 8/18 \u25cfTestosterone-CLIA Waiver Study \u25cfVitamin D-CLIA Submission 5/22\u25cfTestosterone-510k Submission 7/21\u25cfTestosterone-CLIA Waiver Submission 12/25 \u25cfTestosterone- Design Verification Review 3/24\u25cfTSH-Feasibility 6/16 \u25cfTSH- Design Transfer/Design Validation 9/25, 10/30 \u25cfFP2.0 Analyzer Production - Setup Production Line/Training/QC Documents 3/6\u25cfFP2.0 Analyzer Pilot Builds 1 through 3 8/14\u25cfPSA-Feasibility 12/15 \u25cfPouch Production Line \u2013 Hardware/Software Design 1/9\u25cfPouch Production Line - Acceptance Review 7/7\u25cfFT4-Feasibility 12/15 \u25cfPouch Production Line Installation 8/18\u25cfPouch Production Line in service 10/20 ($200K) Milestones in progress and on schedule (Dates shown are projected start and completion dates)\u25cfTestosterone-Design Transfer/Design Validation (3/27 - 5/26)\u25cfTestosterone-CLIA Waiver Study (7/17 - 10/13)\u25cfTSH-Clinical Studies (11/27 - 12/29) \u25cfTSH-Feasibility (1/9 - 6/16) \u25cfTSH- Design Verification (6/19 - 9/22)\u25cfPSA-Design Verification (12/18 - \u25cfFP2.0 Analyzer Production \u2013 Order Parts (3/7 - 7/24)\u25cfTSH- Design Transfer/ Design Validation (9/25 \u2013 11/24)\u25cfFT4-Design Verification (12/18 - \u25cfPouch Production Line Fabrication (3/6 - 5/12)\u25cfPSA-Feasibility (7/10 - 12/15) \u25cfPouch Production Machine Acceptance Test ($600K on 7/17/17)\u25cfFT4-Feasibility (7/10 - 12/15) \u25cfPouch Production Line Training (8/21 - 9/1) Exhibit C- 2 Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020 Exhibit C Development Plan April 28, 2016 FY 2018 Target Review Month April 2018 August 2018 January 2019 Payment ($000) $365 $232 $100 Payment Due Date May 1, 2018 September 1, 2018 February 1, 2019 Criteria for Payment Milestones Completed (Dates shown are projected Completion dates)\u25cfTSH-510k Submission 1/19 \u25cfTestosterone-Commercialized 6/4 \u25cfTSH-Commercialized 12/3 \u25cfTSH-CE Mark 2/16 \u25cfTSH-510k Clearance 6/22 \u25cfPSA-CLIA Waiver Study 9/14 \u25cfTSH-CLIA Waiver Study 4/13 \u25cfTSH-CLIA Waiver Submission 6/25\u25cfPSA-510k Clearance 12/21 \u25cfPSA- Design Verification 3/9 \u25cfPSA-CE mark 7/23 \u25cfPSA-CLIA Submission 12/24 \u25cfFT4- Design Verification 3/9 \u25cfFT4-CE mark 7/23 \u25cfFT4-CLIA Waiver Study 9/14 \u25cfFT4-510 Clearance 12/21 \u25cfFT4-CLIA Submission 12/24 Milestones in progress and on schedule (Dates shown are projected start and completion dates)\u25cfTestosterone CLIA Waiver Submission under review (12- 26 - 4/30)\u25cfTSH-CLIA Waiver Submission under review (6/26 - 10/29) \u25cfPSA- Design Transfer/ Design Validation (3/26 \u2013 5/25)\u25cfPSA-CLIA Waiver Study (7/16 - \u25cfFT4- Design Transfer/ Design Validation (3/26 \u2013 5/25)\u25cfFT4-CLIA Waiver Study (7/16 - \u25cfPayments made based on progress against the Development Plan as evidenced by completion of milestones indicated and progress against milestones yet to be completed. Target review month is estimated timing only.",
    "ollama_generated": "Milestones Achieved (Dates shown are projected Achievement dates) \\*\\*\n\n* Vitamin D-CE Mark 1/13\n* Vitamin D-510k Clearance 5/19\n* Vitamin D-Commercialized 10/30\n* Vitamin D-CLIA Waiver Study 3/10 (reverse condition: Study submitted for CLIA Waiver by specified date)\n* Vitamin D-CLIA Submission 5/22 (reverse condition: CLIA Waiver to be studied by specified date)\n* Testosterone-510k Clearance (pending)\n* Vitamin D-510k Clearance 5/19\n* Testosterone-CE Mark 8/18\n* Testosterone-CLIA Waiver Study (to be determined)\n* Vitamin D-CLIA Submission 5/22\n* Testosterone-510k Submission 7/21\n* Testosterone-CLIA Waiver Submission 12/25 (reverse condition: Submission to be completed by specified date)\n* Testosterone- Design Verification Review 3/24\n* TSH-Feasibility 6/16\n* TSH- Design Transfer/Design Validation 9/25, 10/30 (reverse condition: Design Transfer and Validation to be completed by specified dates)\n* FP2.0 Analyzer Production - Setup Production Line/Training/QC Documents 3/6\n* FP2.0 Analyzer Pilot Builds 1 through 3 8/14\n* PSA-Feasibility 12/15\n* Pouch Production Line \u2013 Hardware/Software Design 1/9\n* Pouch Production Line - Acceptance Review 7/7\n* FT4-Feasibility 12/15\n* Pouch Production Line Installation 8/18\n* Pouch Production Line in service 10/20 ($200K) Milestones under development and on schedule (Dates shown are projected start and completion dates)\n* Testosterone-CLIA Waiver Study (under review from 12-26 to 4/30)\n* TSH-CLIA Waiver Submission (under review from 6/26 to 10/29)\n* PSA- Design Transfer/ Design Validation (3/26 \u2013 5/25)\n* PSA-CLIA Waiver Study (in progress until specified date)\n* FT4- Design Transfer/ Design Validation (3/26 \u2013 5/25)\n* FT4-CLIA Waiver Study (in progress until specified date)\n\nPayments will be made based on the progress against the Development Plan as evidenced by the completion of milestones and the progress towards milestones yet to be completed. The target review month is an estimated timing only.",
    "contradiction_score": 0.2145029455423355,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 184,
    "start_char": 111948,
    "end_char": 112355,
    "original": "\u25cfCompletion of milestones will be based upon the completion of the deliverables, to Sekisui\u2019s satisfaction, in accordance with Qualigen\u2019s standard product development practices as defined in Qualigen\u2019s Quality System Procedure Document #91000002 Rev018. Key terms, such as Feasibility, Verification, Validation and Transfer, are also defined in Qualigen\u2019s Quality System Procedure Document #91000002 Rev018.",
    "ollama_generated": "Milestones completion shall be contingent upon the approval of Sekisui, following the successful delivery of the required materials, which adhere to Qualigen's standard product development practices as outlined in the Quality System Procedure Document #91000002 Rev018. Notably, critical terms like Feasibility, Verification, Validation, and Transfer are also delineated within the Quality System Procedure Document #91000002 Rev018.\n\nIn this version, the responsibility for approving milestones is shifted to Sekisui, making it contingent upon their approval rather than the satisfaction of their requirements as in the original clause.",
    "contradiction_score": 0.13105566799640656,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 186,
    "start_char": 112847,
    "end_char": 113201,
    "original": "Going forward, transfer prices for Products other than reagent kits  will be set as of each October 1 and April 1 for the prospective 6-month period based on Qualigen\u2019s standard unit cost in effect on the first day of the month prior to the date the new transfer prices are agreed upon (either September 1 and March 1) for the prospective 6-month period.",
    "modified": "Commencing from hereafter, the pricing for Products excluding reagent kits will be determined on a biannual basis, effective on February 1 and August 1, for the subsequent six-month interval. This price will be established using Qualigen's standard unit cost as of the last day of the preceding month (either January 31 and July 31), applicable to the forthcoming six-month period. In essence, any adjustments to transfer prices will be made retrospectively, with the effective date being the aforementioned transition dates.",
    "contradiction_score": 0.5554439425468445,
    "kept": true
  },
  {
    "clause_index": 198,
    "start_char": 118544,
    "end_char": 118660,
    "original": "Procure to Pay 1)Qualigen to provide SD purchasing an SD inventory report by SKU on the first work day of the month.",
    "ollama_generated": "Obligation of Qualigen:\nProvide SD with an SD inventory report, arranged by SKU, within five (5) business days following the start of each calendar month.\n\nThis modification allows some flexibility in the deadline for providing the report and adjusts the expectation from \"first work day\" to \"within five (5) business days\".",
    "contradiction_score": 0.046766579151153564,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 209,
    "start_char": 119773,
    "end_char": 119862,
    "original": "6)Freight charges should be managed as freight collect on Customer account or SD account.",
    "ollama_generated": "6) The Responsibility for Freight Charges shall be borne by the Customer, unless otherwise specified, under a Delivered Duty Paid (DDP) basis, with the option for the Vendor to invoice such charges to the Customer's account if deemed appropriate.",
    "contradiction_score": 0.161631241440773,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 221,
    "start_char": 122107,
    "end_char": 122442,
    "original": "A. Alpha Diagnostics Sp. Z o.o Distribution Agreement dated November 15, 2010 B. Cariad Technologies Ltd. distribution Agreement dated April 15, 2005, as amended May 30, 2005 C. CliniLine, S.A. Distribution Agreement dated February 5, 2003, as amended October 27, 2004 Schedule 2. 1 Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
    "ollama_generated": "In lieu of the aforementioned contractual agreements, namely: A. Alpha Diagnostics Sp. Z o.o Distribution Agreement dated November 15, 2010 B. Cariad Technologies Ltd. distribution Agreement dated April 15, 2005, as amended May 30, 2005 C. CliniLine, S.A. Distribution Agreement dated February 5, 2003, as amended October 27, 2004 (hereafter referred to as the \"Original Agreements\"), we propose an alternate set of terms:\n\nAlternate Clause:\nB. Ritter Pharmaceuticals Inc., in consideration of the Original Agreements, hereby accepts the revised terms and conditions outlined in this document, which supersede and replace the aforementioned agreements. Said revisions shall be effective immediately upon signing by both parties and shall govern any future transactions between the parties. Any disputes arising from these revisions shall be resolved by Ritter Pharmaceuticals Inc., who shall retain the sole discretion to interpret these terms.\n\nIn this context, Ritter Pharmaceuticals Inc. assumes the primary responsibility for interpreting and resolving any disputes arising from the revised terms, effectively shifting the power balance between the parties.",
    "contradiction_score": 0.06720569729804993,
    "kept": false,
    "reason": "low_contradiction"
  }
]